 Voltron Therapeutics, Inc. announced today it has initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine SAV against COVID-19. Voltron will take two different vaccines, with differing sets of targets into preclinical testing, in order to identify the best balance of immune responses for prevention of this pandemic pathogen. HaloVax is being developed in conjunction with Hoth Therapeutics, Inc. HOTH. 